Anti-PD1 immunotherapy in MHC-I dysregulated head and neck cancer promotes metastasis via CD8+ T-cell insufficiency

Anti-PD1 immunotherapy in MHC-I dysregulated head and neck cancer promotes metastasis via CD8+ T-cell insufficiency. Download PDF Explore related subjects Discover the latest articles and news in related subjects. Cancer models Cancer therapy Head and neck cancer Immunotherapeutic Approaches in Head and Neck Squamous Cell Carcinoma Dear Editor, Oral squamous cell carcinoma (OSCC), a specific type of head and neck squamous cell carcinoma (HNSCC), remains a major global healthcare concern.

This is due to its aggressive nature, high recurrence rates, and poor response to standard therapies. To boost the host antitumor immunity, immune checkpoint inhibitors (ICIs), including anti-PD1 antibodies like pembrolizumab and nivolumab, are usesd to treat OSCC. 1 Nevertheless, many patients develop resistance to these immunotherapies, emphasizing the importance of uncovering the precise resistance mechanisms.

2 Although loss of major histocompatibility complex class I (MHC-I) in HNSCC has been correlated with resistance, its functional significance and mechanism are unknown due to a lack of specific models. The goal of this study was to establish a humanized HNSCC mouse model to determine whether anti-PD1 therapy drives tumor progression in MHC-I-dysregulated HNSCC. To investigate the therapeutic efficacy of anti-PD1 immunotherapy in MHC-I deficiency, we established a novel orthotopic humanized mouse model (Fig.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.